Pfizer and BioNTech announced they are working on a booster shot for their jointly developed coronavirus vaccine that targets the highly contagious delta variant of the virus.
The companies said Thursday although they believe a third dose of the current two-dose vaccine can provide the “highest levels” of protection against all known variants, including delta, they are nonetheless working on an updated version of the vaccine.
“As seen in the real-world evidence released from the Israel Ministry of Health, vaccine efficacy has declined six months post-vaccination, at the same time that the delta variant is becoming the dominant variant in the country,” the companies said in a statement, CNBC reported.
A third shot may be necessary six to 12 months after vaccination, the companies said, adding that they will seek U.S. authorization for their booster shot in the near future, CNBC reported.

WI Guest Author

This correspondent is a guest contributor to The Washington Informer.

Leave a comment

Your email address will not be published.